Volume 373, Issue 9668, Pages (March 2009)

Slides:

Advertisements

Similar presentations

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Advertisements

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial Bruce.

Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study Dr Jack R W Brownrigg,

Volume 370, Issue 9586, Pages (August 2007)

Volume 386, Issue 10006, Pages (November 2015)

Volume 389, Issue 10074, Pages (March 2017)

Volume 379, Issue 9824, Pages (April 2012)

Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled.

Volume 384, Issue 9961, Pages (December 2014)

Volume 387, Issue 10022, Pages (March 2016)

Copyright © 2015 American Medical Association. All rights reserved.

Volume 357, Issue 9257, Pages (March 2001)

The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis Dr Michael Roerecke, PhD, Prof Janusz Kaczorowski,

Volume 359, Issue 9322, Pages (June 2002)

Volume 349, Issue 9057, Pages (April 1997)

Volume 11, Issue 4, Pages (April 2012)

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

Volume 3, Issue 3, Pages (March 2016)

Real-world Clinical Outcomes Among Patients With Type 2 Diabetes Receiving Canagliflozin at a Specialty Diabetes Clinic: Subgroup Analysis by Baseline.

Bipolar treatment efficacy

Volume 376, Issue 9734, Pages (July 2010)

Long-term effects of hormone replacement therapy

Volume 387, Issue 10022, Pages (March 2016)

Meta-analysis of randomised controlled trials

Volume 376, Issue 9734, Pages (July 2010)

Volume 377, Issue 9784, Pages (June 2011)

Volume 366, Issue 9482, Pages (July 2005)

Long-term effects of hormone replacement therapy

Sayed H. Naderi, BMedSci, Jonathan P. Bestwick, MSc, David S. Wald, MD

Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical.

Franz H. Messerli, MD, Sripal Bangalore, MD, MHA

Volume 373, Issue 9677, Pages (May 2009)

Aspirin in the prevention of cancer – Author's reply

Correction to Lancet Diabetes Endocrinol 2015; 3: 263–74

Volume 366, Issue 9482, Pages (July 2005)

Age-specific relevance of usual blood pressure to vascular mortality

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

The Gobi Desert medical kit

Volume 379, Issue 9814, Pages (February 2012)

Incident diabetes in clinical trials of antihypertensive drugs

Mortality risk with dual antiplatelet therapy?

Meta-analysis of randomised controlled trials

Volume 379, Issue 9822, Pages (March 2012)

Successes and failures of current treatment of heart failure

Bruce Neal, Fiona Turnbull The Lancet

Correction to Lancet Diabetes Endocrinol 2015; 3: 263–74

Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled.

Volume 9, Issue 3, Pages (March 2010)

Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical.

Infant-feeding patterns and HIV-1 transmission

Volume 82, Issue 3, Pages (August 2012)

Volume 371, Issue 9627, Pages (May 2008)

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

Volume 377, Issue 9771, Pages (March 2011)

Department of Error The Lancet Volume 369, Issue 9564, (March 2007)

Volume 373, Issue 9668, Pages (March 2009)

Volume 375, Issue 9719, Pages (March 2010)

Volume 375, Issue 9714, Pages (February 2010)

Volume 361, Issue 9352, Pages (January 2003)

Volume 379, Issue 9822, Pages (March 2012)

The Lancet Respiratory Medicine

Muh Geot Wong, Vlado Perkovic The Lancet Diabetes & Endocrinology

The kidney, a cardiovascular risk marker, and a new target for therapy

Task sharing with non-physician health-care workers for management of blood pressure in low-income and middle-income countries: a systematic review and.

Volume 73, Issue 8, Pages (April 2008)

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised.

Volume 83, Issue 3, Pages (March 2013)

The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis Dr Michael Roerecke, PhD, Prof Janusz Kaczorowski,

Clinic attendance and disengagement of young adults with type 1 diabetes after transition of care from paediatric to adult services (TrACeD): a randomised,

Effect of consent rituals on mortality in emergency care research

Presentation transcript:

Volume 373, Issue 9668, Pages 1009-1015 (March 2009) Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials Hiddo J Lambers Heerspink, PharmD, Toshiharu Ninomiya, MD, Sophia Zoungas, MD, Prof Dick de Zeeuw, MD, Prof Diederick E Grobbee, MD, Meg J Jardine, MD, Martin Gallagher, MD, Matthew A Roberts, MD, Prof Alan Cass, MD, Prof Bruce Neal, MD, Dr Vlado Perkovic, MD The Lancet Volume 373, Issue 9668, Pages 1009-1015 (March 2009) DOI: 10.1016/S0140-6736(09)60212-9 Copyright © 2009 Elsevier Ltd Terms and Conditions

Figure 1 Identification process for eligible studies *Searches on http://www.ClinicalTrials.gov. The Lancet 2009 373, 1009-1015DOI: (10.1016/S0140-6736(09)60212-9) Copyright © 2009 Elsevier Ltd Terms and Conditions

Figure 2 Risk of cardiovascular events for blood pressure lowering treatment versus control regimens DBP=diastolic blood pressure. SBP=systolic blood pressure. NA=not applicable. The overall mean difference in systolic and diastolic blood pressure in the active treatment group compared with the control group is also shown. Negative values indicate lower mean follow-up blood pressure in the active treatment group. The Lancet 2009 373, 1009-1015DOI: (10.1016/S0140-6736(09)60212-9) Copyright © 2009 Elsevier Ltd Terms and Conditions

Figure 3 Subgroup analyses for the effects of blood pressure lowering agents on cardiovascular events ACE=angiotensin-converting enzyme. ARB=angiotensin-receptor blocker. The Lancet 2009 373, 1009-1015DOI: (10.1016/S0140-6736(09)60212-9) Copyright © 2009 Elsevier Ltd Terms and Conditions

Figure 4 Risk of all-cause mortality and cardiovascular mortality for blood pressure lowering treatment versus control regimens NR=not reported. The Lancet 2009 373, 1009-1015DOI: (10.1016/S0140-6736(09)60212-9) Copyright © 2009 Elsevier Ltd Terms and Conditions